ADCendo
Copenhagen
About ADCendo
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $249.6M
- Funding stage: Early Stage Venture
- Last round: Series B (Nov 2024)
- Website: adcendo.dk
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/adcendo-117649 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.